GlassScriptPhysician profile
Nilesh J Patel
NPI 1710099262
$3,386.56
in general payments reported to CMS, 2019-2025
21 companies · $307 in 2025
The $307 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $117 · 2021: $578 · 2022: $661 · 2023: $594 · 2024: $698 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $775.34 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $562.01 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $342.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $274.49 | 2019-2024 | |
| Abbvie INC. | $243.80 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $191.72 | 2021-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $125.17 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.53 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $104.66 | 2022-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $96.62 | 2019-2020 | |
| Gilead Sciences, INC. | $90.93 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $89.00 | 2022-2024 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $76.60 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $65.07 | 2024 | |
| Janssen Biotech, INC. | $48.09 | 2025 | Talvey, Tecvayli, Stelara |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $41.36 | 2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.32 | 2021-2022 | |
| Depuy Synthes Sales INC. | $34.65 | 2024 | Matrixrib |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.08 | 2023-2025 | Lifevest |
| Amgen INC. | $27.22 | 2019 | |
| Recordati_rare_diseases_inc. | $20.35 | 2024 | Panhematin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.